Medicine and Dentistry
Transanal Endoscopic Microsurgery
95%
Transanal Endoscopic Surgery
83%
Rectum Tumor
48%
Neoplasm
44%
Surgery
44%
Rectum Cancer
42%
Observational Study
41%
Total Mesorectal Excision
36%
Recurrent Disease
32%
Postoperative Complication
31%
Adenocarcinoma
29%
Surgical Anastomosis
28%
Diverticulitis
21%
Rectum Adenoma
21%
Colorectal Carcinoma
19%
Anal Verge
17%
Randomized Controlled Trial
17%
Surgeon
17%
Colorectal Surgery
16%
Laparoscopic Surgery
16%
Parastomal Hernia
15%
Chemoradiotherapy
15%
Colectomy
15%
Local Excision
14%
Surgical Infection
13%
Operation Duration
13%
Suture
13%
Outpatient
13%
Sphincter
12%
Cancer Surgery
11%
Hemicolectomy
11%
Anal Canal
11%
Noninferiority Trial
10%
Endoscopic Surgery
10%
Randomized Clinical Trial
10%
Prospective Cohort Study
10%
Colon Surgery
10%
Bowel Obstruction
10%
Morbidity
10%
Rectum Carcinoma
10%
Recurrence Risk
10%
Colon
9%
Colostomy
9%
Peritoneal Cavity
9%
Surgical Margin
9%
End to End Anastomosis
9%
Adenoma
8%
Submucosa
8%
Antibiotics
7%
Urinary System
7%
Keyphrases
Transanal Endoscopic Microsurgery
100%
Transanal Endoscopic Surgery
87%
Rectal Tumor
49%
Transanal Total Mesorectal Excision (taTME)
36%
Colorectal Cancer
36%
Resection
32%
Adenocarcinoma
29%
Anastomosis
26%
Colorectal Surgery
25%
Postoperative Complications
23%
Tumor
22%
Intracorporeal
21%
Acute Diverticulitis
21%
Anal Verge
19%
Rectal Adenoma
18%
Transanal
18%
Transanal Endoscopic Operation
17%
Prospective Data Collection
16%
Parastomal Hernia
15%
Rectal Adenocarcinoma
15%
Laparoscopic Approach
15%
Pacientes
13%
Prospective Randomized Trial
13%
Postoperative Morbidity
12%
Left Colon
12%
Surgeons
12%
Local Recurrence
12%
Hospital Stay
12%
Local Surgery
12%
Anal Canal
11%
Perforation
11%
Left-handed
11%
Intracorporeal Anastomosis
11%
Confidence Interval
11%
Excision
11%
Rectal Prolapse
11%
Surgical Time
11%
Adenoma
11%
Morbidity Rate
10%
Consecutive Patients
10%
Non-inferiority Trial
10%
Left-sided Colectomy
10%
Robotics
10%
Randomized Controlled Trial
10%
Colon Surgery
10%
Inclusion Criteria
10%
Outpatient Treatment
9%
CoMoS
9%
Long-term Oncological Outcomes
9%
Peritoneal Cavity
9%